Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride
RATIONALE: Studying samples of blood in the laboratory from patients receiving erlotinib hydrochloride may help doctors learn more about the effects of erlotinib hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research study is studying biomarkers predicting response in patients with non-small cell lung cancer previously treated with erlotinib hydrochloride.
|Lung Cancer||Other: enzyme-linked immunosorbent assay Other: laboratory biomarker analysis|
|Study Design:||Observational Model: Other
Time Perspective: Retrospective
|Official Title:||Measurement of Potential Biomarkers Predicting Erlotinib Response|
- Baseline serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin levels as predictors of erlotinib hydrochloride response [ Time Frame: 1 month ]
|Actual Study Start Date:||April 12, 2010|
|Study Completion Date:||June 12, 2010|
|Primary Completion Date:||June 12, 2010 (Final data collection date for primary outcome measure)|
- To evaluate whether serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin can be utilized as biomarkers to predict response in patients with non-small cell lung cancer treated with erlotinib hydrochloride.
OUTLINE: Serum samples are analyzed for NGAL, MMP-9, NGAL/MMP-9, and soluble E-cadherin by ELISA and Luminex assays.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01123460
|Principal Investigator:||Steven M. Dubinett, MD||Jonsson Comprehensive Cancer Center|